Washington, D.C. (January 31, 2017) — The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors elected new officers and welcomed a new member company today.
Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, was elected chairman of the board of directors. Joseph Jimenez, CEO, Novartis AG, was elected chairman-elect and Robert A. Bradway, chairman and CEO, Amgen, assumed the role of board treasurer. Duato assumed the position of board chairman in early January following the departure of Dr. George Scangos from Biogen.
In addition to the election of new officers, PhRMA announced UCB, Inc., Smyrna, Georgia, as a new member.
“I am pleased to welcome Joaquin Duato, Joseph Jimenez and Robert Bradway to their new leadership roles at PhRMA and UCB as a new member,” said PhRMA president and CEO Stephen J. Ubl. “I, and our entire team, look forward to working with them to convene stakeholders across the health care system to discuss new innovative ways to pay for medicines and advance patient-focused solutions. Biopharmaceutical science is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines produced by our companies.”
“I am honored to lead this talented executive team during such a pivotal time in defining the future of America’s health care system. Together with Steve Ubl, we will ensure that PhRMA is a collaborative and inclusive voice, bringing positive, pragmatic solutions forward to make our health care system work better for patients,” said Duato.
Jimenez has been CEO of Novartis since 2010. He joined the company in 2007 as division head, Novartis Consumer Health and held the position of division head, Novartis Pharmaceuticals prior to the role of CEO. Previously, he served as president and CEO of the North American and European businesses for the H.J. Heinz Company and on the board of directors of Colgate Palmolive Co. and AstraZeneca PLC. He currently serves on the board of General Motors Co. Jimenez holds a bachelor’s degree from Stanford University and a Master of Business Administration from the University of California, Berkeley.
“For patients to truly benefit from the new era of medicine, there is a critical need for greater collaboration in the health care ecosystem,” said Jimenez. “PhRMA is making important strides in this effort, and I look forward to more widely representing the industry in the move toward a value-driven health care system.”
Bradway has been Amgen’s chairman since 2013 and CEO since 2012. He joined the company in 2006 and served as the company’s president and chief operating officer prior to the role of CEO. Previously, Bradway was managing director at Morgan Stanley in London. He is a member of the board of directors of Norfolk Southern Corporation and The Boeing Company. Bradway serves on the board of trustees of the University of Southern California and the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is also chairman of the CEO Roundtable on Cancer. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.
“Helping patients and addressing the burden of disease is what drives the men and women of this industry every single day,” said Bradway. “We are seeing the power of innovation in every aspect of today’s approaches to medical discovery and are eager to demonstrate how bold advancements in innovation can address the costs of disease.”
UCB, Inc. is a division of UCB, Brussels, Belgium, a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7,500 people in approximately 40 countries, UCB, Brussels, Belgium generated revenue of more than U.S. $4 billion in 2015.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.